ZHUBEI,April 17,2025 -- BrainNavi Biotechnology Co.,Ltd. ("Brain Navi") has officially begun IPO counseling with First Securities Inc.,marking a strategic step toward accessing the capital markets and advancing its long-term growth in the surgical robot technology industry.

Dr. Jerry Chen,CEO of Brain Navi,announced the IPO Consulting to enter the capital market.

Founded in 2015 and located in the Hsinchu Biomedical Science Park,Brain Navi concentrates on innovating surgical robots and medical devices. By integrating machine vision,artificial intelligence (AI),and advanced navigation technologies,the company provides high-precision surgical solutions tailored to meet the evolving needs of modern healthcare. Over the years,Brain Navi has established strong partnerships with leading medical institutions worldwide. Its innovations have garnered multiple international patents and regulatory approvals,with global expansion efforts already underway in Europe,Asia,Latin America,and soon in the USA market.

The company's flagship product,NaoTrac,is a neurosurgical navigation robot that combines AI,robotics,and computer vision to enhance surgical precision and reduce operative time. Brain Navi's portfolio also includes the KrystoLens,the single-use neuro-endoscope designed to improve safety and efficiency in minimally invasive brain surgery.

Looking ahead,Brain Navi plans to deepen collaborations with top-tier medical centers to refine its intelligent surgical systems. Through this IPO counseling process,the company aims to responsibly accelerate R&D and scale its innovations for broader clinical adoption,reinforcing its position as a next-generation leader in smart medical technology.

First Securities Inc. expressed confidence in Brain Navi's growth potential. As global interest in surgical robotics continues to rise—especially in neurosurgery,where accuracy is critical—technologies that combine navigation and AI are poised to play a transformative role. The firm will provide continued guidance throughout Brain Navi's IPO journey,helping bring new investment opportunities to those who share a vision for the future of intelligent healthcare.